Palod Distributors-Home Page
Home Page About Us Products Group Companies Scheme Our Videos Contact Us
News Detail
Oct. 13 2014
grown by 578 Crores over Aug-14 & 1227 Crs over Sep -13. > The Seasonal spike seen in 2012 from July onwards, which > peaks in Sep/Oct and comes down in Nov, was not observed > last year due to DPCO / NLEM issues. Hence we are > entering a phase where on
We have > grown by 578 Crores over Aug-14 & 1227 Crs over Sep -13. > The Seasonal spike seen in 2012 from July onwards, which > peaks in Sep/Oct and comes down in Nov, was not observed > last year due to DPCO / NLEM issues. Hence we are > entering a phase where on low base of last year – the > growth rates are expected to be in strong double digits for > the next 3-4 months >

We have
> grown by 578 Crores over Aug-14 & 1227 Crs over Sep -13.
> The Seasonal spike seen in 2012 from July onwards, which
> peaks in Sep/Oct and comes down in Nov, was not observed
> last year due to DPCO / NLEM issues. Hence we are
> entering a phase where on low base of last year – the
> growth rates are expected to be in strong double digits for
> the next 3-4 months
> 2.
> For Month
> of Sep -14, we have seen the GDs as 11.0% in Volumes, 4.5%
> in Price Increases & 3.3% in NIs against a -4.9% in
> volumes in Sep -13 3.
> There has
> been a growth registered (12.3%) in this quarter
> which is higher than previous quarter (9.5%) & also
> against the corresponding Quarter last year
> (4.3%)
> Major Highlights for
> Month of September 2014: Ø September Month
> Highlights:Ø The IPM clocked 7738 Crs in September
> 2014Ø The Indian Pharma Market grows at
> 18.8% for the month of September 2014
> Ø Corporates:Ø For the month of September 2014,
> amongst the top 10, Cipla grew by 38.4% followed by Mankind
> at 30.9% & Pfizer at 23.9%Ø Cipla became the No 1 company for the
> month of Sep -14Ø 23 corporates have crossed the growth
> of IPM for the month of September 2014 amongst top 50
> Ø Amongst the top 50 Corporates,
> Akumentis has the highest growth of 92.5% followed by Apex
> at 62.2% & Bharat Serums at 49.9%Ø 12 Corporates showed growths more
> than 30% amongst the top 50Ø Amongst the 11-20 ranked corporates
> Macleods has the highest growth of 44.2% followed by Aristo
> at 39.7% & Glenmark at 27.0%Ø Amongst the 51-60 ranked corporates,
> Eli Lilly grows at 34.9% followed by Allergan at 31.3% &
> Pharmed at 26.0%Ø Amongst the 61-75 ranked corporates,
> Boehringer grew by 88.8% followed by Corona at 27.8% and
> British Biological at 27.4% Ø Indian V/S
> MNCs:Ø Indian companies have grown at 19.8%
> versus 16.0% for MNCs in September 2014Ø Amongst the top 50 in MNCs Pfizer
> grew by 23.9% followed by Janssen at 18.8% & Abbott* at
> 16.7%Ø Under the Non-NLEM category Indian
> Companies grew at 21.7% whereas MNCs grew at
> 17.8% Ø DPCO V/s Non DPCO
> Market:Ø The DPCO 2013 containing molecules
> market grew at 10.8% whereas the non DPCO market grew by
> 20.7% resulting in an overall growth of 18.8% for September
> 2014Ø NLEM & Non - NLEM Category showed
> positive unit growth at 6.6% and 12.1%
> respectivelyØ The DPCO 2013 portfolio for
> Pfizer grew at 6.2%, GSK 12.9%, Ranbaxy 19.7% Ø Therapy:Ø From therapy perspective 9 therapies
> have outgrown the IPM growth & 18 therapies have double
> digit growthsØ Respiratory Market grew at 28.6%,
> Gastrointestinal market grew at 19.4% , Pain &
> Analgesics market grew at 17.7% whereas Anti-infectives grew
> at 23.3%Ø Anti-diabetic market grows at 24.6%
> & Cardiac at 13.1% in chronic businessØ Derma market grew by 19.1% &
> Urology Market at 29.9%
> Ø Regional
> Dynamics:Ø From regional perspective 13 regions
> have outgrown the IPM growthØ Jharkhand market grew the highest at
> 36.4% followed by Vidarbha Market at 32.5% & Madhya
> Pradesh Market at 32.3% Ø No region had negative growth in
> September 2014  Ø Molecules:Ø Amoxycillin + Clavulanic Acid Market
> grows at 34.0% whereas Glimepiride + Metformin grows at
> 13.3% at No 2.Ø The markets of Paracetamol grew at
> 28.1%, Atorvastatin 14.7%, Azithromycin at 39.7%, Probiotic
> Microbes at 40.3%, Cefixime 21.0%, Pantoprazole
> 21.0%Montelukast + Levocetrizine at 36.6%, Glimepiride +
> Metformin + Pioglitazone at 18.6%, Vitamin-D at 39.6%,
> Hydroquinone + Mometasone + Tretinoin at 13.3%, Voglibose +
> Metformin + Glimepiride at 39.1%, Telmisartan + Metoprolol
> at 41.3%
> Ø Brands:Ø Mixtard continues to lead the pack
> with 35.2 Crs for the Month of Sep -14 with a growth of
> 38.8%Ø Augmentin grows at 52.1%, followed by
> Monocef at 45.7 % & Lantus at 42.2% amongst the top 10
> Brands Ø Amongst the Brands who have gained
> ranks include Augmentin & Glycomet-GP (+1), Lantus
> (+9), Galvus Met (+6), Taxim-O (+4),
> Moxikind CV (+7), Spasmoproxyvon Plus (+37), Zincovit
> (+17), Thyronorm (+27), Novomix (+12),Panderm Plus (+77),
> Jalra M (+29), Sinarest (+5), Shelcal (+16) amongst Top 100
> Brands over September 13 Ø On MAT Basis, Bifilac enters into Top
> 300 BrandsØ Amongst the top brands in the
> IPM, Spasmoproxyvon Plus (67.0%), Augmentin (52.1%),
> Monocef (45.7%), Taxim O (33.0%), Aciloc (26.2%),Dexorange
> (22.7%), Liv-52(19.5%), Glycomet-GP (14.9%) grew
> fastest amongst the top 30 Brands over September
> 2013 Ø New
> Launches in IPM:Ø Total 283 Brands launched in
> September 2014Ø Felbinac is a new subgroup launched
> in Sep 2014 Therapy Perspective:
> AWACS wishes all of you a very
> Happy Diwali BR

 

With Bonus Units at Full Value   Without Bonus Units
Rank MAT Sep -14 Sep-14 Val in Crs Rank MAT Sep -14 Sep-14
MAT MTH Val (Cr) MS% GR% Val (Cr) MS% GR% CORPORATE MAT MTH Val (Cr) MS% GR% Val (Cr) MS% GR%
    80565 100.00 9.1 7738 100.00 18.8 IPM     77530 100.00 9.2 7421 100.00 18.6
1 1 5030 6.24 5.8 467 6.03 16.7 Abbott + Abbott HC + Novo 1 1 4934 6.36 5.8 457 6.15 16.9
2 3 4343 5.39 15.0 378 4.89 8.9 Sun Pharma 2 3 4241 5.47 14.2 368 4.95 8.1
3 2 4038 5.01 10.3 427 5.51 38.4 Cipla 3 2 3799 4.90 12.6 399 5.38 38.7
4 4 3480 4.32 8.0 312 4.03 12.0 Zydus + Biochem 4 4 3254 4.20 7.7 292 3.94 11.1
5 7 2908 3.61 4.9 273 3.53 15.8 Ranbaxy 5 7 2799 3.61 5.2 262 3.53 15.8
6 5 2899 3.60 10.2 305 3.95 30.9 Mankind 9 6 2475 3.19 12.1 265 3.57 33.7
7 6 2887 3.58 13.8 290 3.75 19.1 Alkem + Cachet + Indchemie 7 5 2692 3.47 14.5 270 3.64 20.0
8 8 2729 3.39 -11.1 264 3.41 14.9 Glaxo 6 8 2704 3.49 -10.1 262 3.53 15.5
9 9 2710 3.36 12.8 259 3.35 19.7 Lupin 8 9 2654 3.42 13.0 254 3.42 20.3
10 12 2348 2.91 6.3 229 2.96 23.9 Pfizer 10 11 2298 2.96 6.7 224 3.02 23.9
11 10 2279 2.83 21.4 244 3.15 44.2 Macleods 11 10 2135 2.75 21.2 226 3.05 43.9
12 14 2193 2.72 11.1 191 2.47 4.9 Emcure + Zuventus 12 14 2127 2.74 11.4 184 2.48 4.7
13 13 2098 2.60 15.3 195 2.51 18.8 Intas 13 13 2070 2.67 15.6 192 2.59 19.0
14 11 2023 2.51 19.9 230 2.98 39.7 Aristo 15 12 1772 2.29 17.4 198 2.67 36.1
15 16 1984 2.46 -0.5 180 2.32 13.2 Sanofi India 14 16 1944 2.51 -0.7 175 2.36 12.5
16 18 1779 2.21 5.4 167 2.15 18.4 Torrent 16 17 1744 2.25 5.7 163 2.20 18.3
17 15 1754 2.18 16.6 185 2.39 27.0 Glenmark 17 15 1701 2.19 16.2 179 2.41 26.4
18 17 1719 2.13 9.4 167 2.15 17.5 Dr. Reddys 18 18 1682 2.17 8.6 162 2.18 16.7
19 20 1616 2.01 12.0 143 1.85 4.6 Micro + Bal 19 20 1546 1.99 12.5 136 1.83 4.1
20 19 1470 1.82 24.7 152 1.96 22.1 Ipca 21 19 1404 1.81 25.0 145 1.95 22.5
21 21 1466 1.82 10.0 128 1.66 7.6 USV 20 21 1460 1.88 10.1 128 1.72 7.8
22 23 1145 1.42 -1.0 105 1.36 13.4 Novartis 22 23 1108 1.43 0.0 102 1.38 14.3
23 22 1103 1.37 12.8 117 1.51 30.6 Alembic 23 22 1072 1.38 13.5 114 1.53 31.3
24 25 993 1.23 6.1 84 1.09 7.6 Wockhardt 24 25 974 1.26 6.2 83 1.11 7.4
25 24 843 1.05 6.8 90 1.16 24.0 FDC 25 24 819 1.06 6.7 87 1.18 24.0
26 26 815 1.01 10.7 77 0.99 13.0 Unichem 26 26 797 1.03 10.3 75 1.01 12.8
27 27 794 0.99 12.9 70 0.90 10.0 MSD + Fulford + Organon 27 27 783 1.01 12.6 68 0.92 9.5
28 29 687 0.85 16.0 60 0.78 9.6 Cadila 28 29 665 0.86 16.1 58 0.78 9.2
29 28 633 0.79 13.4 68 0.88 34.4 Indoco Remedies 29 28 593 0.76 13.4 63 0.85 33.7
30 30 590 0.73 12.5 56 0.73 13.1 Franco 31 30 569 0.73 11.9 54 0.73 12.6
31 31 581 0.72 18.1 49 0.64 12.2 Eris 30 31 578 0.74 17.9 49 0.66 12.4
32 33 491 0.61 8.3 48 0.62 17.2 Himalaya 32 32 489 0.63 8.0 48 0.64 17.0
33 32 483 0.60 10.4 48 0.62 21.6 Merck 33 33 471 0.61 9.4 46 0.63 21.1
34 34 441 0.55 6.3 47 0.60 27.1 Blue Cross 35 36 405 0.52 7.1 42 0.57 26.5
35 36 441 0.55 16.6 45 0.58 41.5 JB Chemicals 34 35 424 0.55 16.7 43 0.59 42.4
36 38 398 0.49 -6.4 43 0.55 49.9 Bharat Serums 37 37 391 0.50 -6.8 42 0.57 49.5
37 47 396 0.49 -0.2 30 0.38 -18.0 Astrazeneca 36 47 392 0.51 -0.6 29 0.40 -17.7
38 39 391 0.49 22.6 38 0.50 23.9 Meyer Organics
eXpert Solution by
North South Technologies Pvt. Ltd.